Latest news with #Actrapid
Time of India
25-04-2025
- Business
- Time of India
Novo Nordisk to continue India's largest insulin brand Mixtard supply in vials
Representative image Novo Nordisk has stated that its flagship insulin brand Mixtard will continue to be available in India in vial form, even as the company phases out other delivery formats such as Penfill cartridges. The announcement comes amid widespread concern over the discontinuation of some of the country's most-used insulin products. Responding to TOI reports that it was withdrawing Mixtard—India's top-selling insulin brand with annual sales of over Rs 800 crore, Novo Nordisk said in a statement. 'In order to meet increasing patient demand and ensure a stable supply of our medicines, we have decided to consolidate our insulin portfolio. This will create space needed in our global manufacturing network,' 'Hence, in this process, we are phasing out the Penfill. We acknowledge that this will be disruptive to people living with diabetes who rely on our treatments. However, by doing this now, we will increase the number of patients we reach with our insulin portfolio by many millions in the next decade," it added. This comes after reports that the Danish drugmaker was discontinuing Human Mixtard—India's largest-selling insulin brand—and other older-generation insulins from the market. The TOI report noted that Human Mixtard, a Rs 800 crore brand despite being under price control, along with products like Actrapid, Insulatard, Insulin Detemir, Levemir, and Xultophy, would no longer be available in popular delivery formats such as pre-filled pens and cartridges (Penfill and FlexPen). Read report: Novo Nordisk to phase out country's largest insulin brand The Danish pharmaceutical giant reassured patients that the insulin, along with other human insulins like Actrapid and Insulatard, will still be accessible in vials across India. These vials are administered through traditional syringes. According to documents cited in the earlier report, Novo Nordisk had informed its marketing partner Abbott India that the products would be withdrawn once current stocks were exhausted, a process expected to take around six months. The move is reportedly part of the company's global strategy to shift focus toward newer, more profitable treatments such as Ozempic and Wegovy , which it plans to introduce in the Indian market this year. As part of this shift, earlier-generation insulin products are being gradually phased out worldwide. Stay informed with the latest business news, updates on bank holidays and public holidays . Master Value & Valuation with ET! Learn to invest smartly & decode financials. Limited seats at 33% off – Enroll now!
Time of India
25-04-2025
- Health
- Time of India
Novo Nordisk to continue largest insulin brand Mixtard supply in vials amid penfill device phase-out
Representative image Novo Nordisk has stated that its flagship insulin brand Mixtard will continue to be available in India in vial form, even as the company phases out other delivery formats such as Penfill cartridges, in a response to a Times of India report. The announcement comes amid widespread concern over the discontinuation of some of the country's most-used insulin products. Responding to reports that it was withdrawing Mixtard—India's top-selling insulin brand with annual sales of over Rs 800 crore—the Danish pharmaceutical giant reassured patients that the insulin, along with other human insulins like Actrapid and Insulatard, will still be accessible in vials across India. These vials are administered through traditional syringes. 'In order to meet increasing patient demand and ensure a stable supply of our medicines, we have decided to consolidate our insulin portfolio. This will create space needed in our global manufacturing network,' Novo Nordisk said in a statement. 'Hence, in this process, we are phasing out the Penfill. We acknowledge that this will be disruptive to people living with diabetes who rely on our treatments. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play this game for 3 minutes, if you own a mouse Undo However, by doing this now, we will increase the number of patients we reach with our insulin portfolio by many millions in the next decade. ' This comes after reports that the Danish drugmaker was discontinuing Human Mixtard—India's largest-selling insulin brand—and other older-generation insulins from the market. The TOI report noted that Human Mixtard, a Rs 800 crore brand despite being under price control, along with products like Actrapid, Insulatard, Insulin Detemir, Levemir, and Xultophy, would no longer be available in popular delivery formats such as pre-filled pens and cartridges (Penfill and FlexPen). Read report: Novo Nordisk to phase out country's largest insulin brand According to documents cited in the earlier report, Novo Nordisk had informed its marketing partner Abbott India that the products would be withdrawn once current stocks were exhausted, a process expected to take around six months. The move is reportedly part of the company's global strategy to shift focus toward newer, more profitable treatments such as Ozempic and Wegovy , which it plans to introduce in the Indian market this year. As part of this shift, earlier-generation insulin products are being gradually phased out worldwide. Stay informed with the latest business news, updates on bank holidays and public holidays . Master Value & Valuation with ET! Learn to invest smartly & decode financials. Limited seats at 33% off – Enroll now!
Time of India
22-04-2025
- Business
- Time of India
Novo Nordisk to discontinue Human Mixtard, India's largest selling insulin brand
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Pharmaceutical giant Novo Nordisk is discontinuing the country's largest selling insulin, Human Mixtard , along with other insulins. The move could shake up the diabetes market, TOI it being under price control, Human Mixtard alone is a Rs 800 crore brand for the company in India. The phase out could further impact the pharmaceutical's top brands in the Rs 5,000 crore insulin market including Actrapid, Insulatard , Insulin Detemir and Levemir and Xultophy, which are marketed primarily in the format of pre-filled disposable pen and cartridges (Penfill and FlexPen).TOI accessed documents that said the company recently informed marketing partner, Abbott India that the products would be discontinued once the current stocks are exhausted. This could take about six decision comes as the Danish company's global strategy to prioritise newer, patented diabetes and weight loss therapies including Ozempic and Wegovy, due to their higher profitability, sources told TOI. It also is in line with its plans to introduce these therapies in the Indian market this Nordisk, as a part of its global strategy is discontinuing earlier generation insulin products the company plans to continue selling Human Mixtard, Actrapid and Insulatard, in vials, which can be delivered to patients through might lead to limited access as insulin delivery from pen devices is preferred by a huge majority of diabetics over vials injected with syringes, due to its accuracy, ease of dosing, and reduced stigma.(With TOI inputs)
Time of India
22-04-2025
- Health
- Time of India
Novo Nordisk to phase out its largest insulin brand in India
In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country's largest selling insulin, Human Mixtard, among other older insulin brands in India. Tired of too many ads? go ad free now Human Mixtard alone is a Rs 800 crore brand for Novo Nordisk in India, despite it being under price control. Besides Human Mixtard, the phase-out could impact its top brands in the Rs 5,000 crore insulin market including Actrapid, Insulatard, Insulin Detemir and Levemir and Xultophy — marketed mostly in the format of pre-filled disposable pen and cartridges (Penfill and FlexPen). The company recently informed its marketing partner, Abbott India that the products would be discontinued once the current stocks are exhausted, documents accessed by TOI said. This could take about six months. The decision is in line with the global strategy of the Danish company to prioritise newer, patented blockbuster diabetes and weight loss therapies including Ozempic and Wegovy , due to their higher profitability, sources said. Also, it seems to be potentially in line with its plans to introduce these therapies in the Indian market this year. As part of its global strategy, earlier generation insulin products will be discontinued globally in a gradual manner. An email sent on April 17 to the company went unanswered. However, the company plans to continue selling Human Mixtard, Actrapid and Insulatard, in vials — which can be delivered to patients through injections. This may limit the access further as insulin delivery from pen devices is preferred by a huge majority of diabetics over vials injected with syringes, due to its accuracy, ease of dosing, and reduced stigma, a survey said earlier.
